DK1689872T3 - Promotorer til ekspression i modificeret vacciniavirus Ankara - Google Patents

Promotorer til ekspression i modificeret vacciniavirus Ankara

Info

Publication number
DK1689872T3
DK1689872T3 DK04790902T DK04790902T DK1689872T3 DK 1689872 T3 DK1689872 T3 DK 1689872T3 DK 04790902 T DK04790902 T DK 04790902T DK 04790902 T DK04790902 T DK 04790902T DK 1689872 T3 DK1689872 T3 DK 1689872T3
Authority
DK
Denmark
Prior art keywords
expression
promoters
vaccinia virus
virus ankara
modified vaccinia
Prior art date
Application number
DK04790902T
Other languages
English (en)
Inventor
Sonja Leyrer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK1689872T3 publication Critical patent/DK1689872T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • A61K39/285Vaccinia virus or variola virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK04790902T 2003-11-24 2004-10-27 Promotorer til ekspression i modificeret vacciniavirus Ankara DK1689872T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301730 2003-11-24
EP04000943A EP1536015B1 (en) 2003-11-24 2004-01-17 Promoters for expression in modified vaccinia virus ankara
PCT/EP2004/012125 WO2005054484A1 (en) 2003-11-24 2004-10-27 Promoters for expression in modified vaccinia virus ankara

Publications (1)

Publication Number Publication Date
DK1689872T3 true DK1689872T3 (da) 2009-04-27

Family

ID=34442836

Family Applications (3)

Application Number Title Priority Date Filing Date
DK04000943T DK1536015T3 (da) 2003-11-24 2004-01-17 Promotorer til ekspression i modificeret vacciniavirus Ankara
DK07014231.0T DK1845164T3 (da) 2003-11-24 2004-01-17 Promoterer til ekspression i modificeret vacciniavirus ankara
DK04790902T DK1689872T3 (da) 2003-11-24 2004-10-27 Promotorer til ekspression i modificeret vacciniavirus Ankara

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK04000943T DK1536015T3 (da) 2003-11-24 2004-01-17 Promotorer til ekspression i modificeret vacciniavirus Ankara
DK07014231.0T DK1845164T3 (da) 2003-11-24 2004-01-17 Promoterer til ekspression i modificeret vacciniavirus ankara

Country Status (18)

Country Link
US (3) US7816508B2 (da)
EP (4) EP1845164B1 (da)
JP (2) JP2007512009A (da)
KR (1) KR20060109873A (da)
CN (1) CN1898390A (da)
AT (4) ATE377088T1 (da)
AU (1) AU2004295382A1 (da)
BR (1) BRPI0416916A (da)
CA (1) CA2546680A1 (da)
DE (4) DE602004027767D1 (da)
DK (3) DK1536015T3 (da)
EA (1) EA012846B1 (da)
IL (4) IL174653A0 (da)
NO (1) NO20062948L (da)
NZ (1) NZ547405A (da)
SG (2) SG142300A1 (da)
UA (1) UA90098C2 (da)
WO (1) WO2005054484A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60116371T3 (de) * 2000-11-23 2016-11-17 Bavarian Nordic A/S Variante des modifizierten vaccinia ankara virus
DE602004027767D1 (de) * 2003-11-24 2010-07-29 Bavarian Nordic As Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
EP2042604A1 (en) * 2007-09-26 2009-04-01 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) VV promoter driven overexpression of recombinant antigens
JP2012509678A (ja) * 2008-11-27 2012-04-26 バヴァリアン・ノルディック・アクティーゼルスカブ 組換えウイルス発現のためのプロモーター
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
US9173933B2 (en) 2010-10-15 2015-11-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara influenza vaccine
DK2788021T3 (da) 2011-12-09 2017-04-10 Bavarian Nordic As Poxvirusvektor til ekspression af bakterielle antigener, der er koblet til tetanustoksinfragment c
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106754921A (zh) * 2016-12-12 2017-05-31 孙浩 哺乳动物细胞表达启动子及其制造和使用方法
EP3621646A4 (en) * 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
MXPA02008873A (es) 2000-03-14 2003-02-10 Anton Mayr Cepa alterada del virus de vaccinia ankara modificado (mva).
DE60116371T3 (de) * 2000-11-23 2016-11-17 Bavarian Nordic A/S Variante des modifizierten vaccinia ankara virus
AU2002252199B2 (en) * 2001-03-08 2008-01-03 Emory University MVA expressing modified HIV envelope, GAG, and POL genes
BR0310020A (pt) 2002-05-16 2005-02-15 Bavarian Nordic As Expressão de genes no vìrus da vacìnia modificado ancara por uso do promotor de ati de vacìnia
ATE504653T1 (de) * 2002-08-07 2011-04-15 Bavarian Nordic As Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
DE602004027767D1 (de) * 2003-11-24 2010-07-29 Bavarian Nordic As Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara

Also Published As

Publication number Publication date
NO20062948L (no) 2006-08-23
ATE420191T1 (de) 2009-01-15
DE602004027767D1 (de) 2010-07-29
EP1956094B1 (en) 2011-04-06
KR20060109873A (ko) 2006-10-23
IL199128A (en) 2011-03-31
EP1689872B1 (en) 2009-01-07
DE602004009743T2 (de) 2008-08-28
DE602004032187D1 (de) 2011-05-19
EP1536015A1 (en) 2005-06-01
DE602004009743D1 (de) 2007-12-13
US20110014242A1 (en) 2011-01-20
EP1956094A1 (en) 2008-08-13
US20080112971A1 (en) 2008-05-15
JP2007512009A (ja) 2007-05-17
JP2011067219A (ja) 2011-04-07
SG142300A1 (en) 2008-05-28
NZ547405A (en) 2008-06-30
ATE377088T1 (de) 2007-11-15
AU2004295382A1 (en) 2005-06-16
UA90098C2 (en) 2010-04-12
IL174653A0 (en) 2006-08-20
DK1845164T3 (da) 2010-09-20
DK1536015T3 (da) 2008-02-18
EP1845164A3 (en) 2008-03-19
ATE504654T1 (de) 2011-04-15
EA200601043A1 (ru) 2006-10-27
SG169325A1 (en) 2011-03-30
EP1845164B1 (en) 2010-06-16
EA012846B1 (ru) 2009-12-30
ATE471383T1 (de) 2010-07-15
CN1898390A (zh) 2007-01-17
CA2546680A1 (en) 2005-06-16
IL199127A (en) 2010-12-30
US20110008792A1 (en) 2011-01-13
BRPI0416916A (pt) 2007-01-23
US7816508B2 (en) 2010-10-19
EP1536015B1 (en) 2007-10-31
EP1845164A2 (en) 2007-10-17
DE602004018975D1 (de) 2009-02-26
EP1689872A1 (en) 2006-08-16
WO2005054484A1 (en) 2005-06-16
IL199126A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
IL199127A (en) Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters
ATE523205T1 (de) Prime-boost-impfstoffe gegen malaria
ATE490262T1 (de) Abschwächung der immunogenizität von fusionsproteinen
HK1076835A1 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
NO20063521L (no) Blandinger, fremgangsmater og anvendelser av en ny peptidfamilie
UA82998C2 (ru) Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
BRPI0516576A (pt) vetores quiméricos
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
DK1675956T3 (da) Minimal DNA-sekvens, der virksom som chromatinisolator, og dennes anvendelse til proteinekspression
CY1109244T1 (el) Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου.
ATE532861T1 (de) Expressionsvektor
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
DE50312368D1 (de) Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria
ATE547530T1 (de) Rekombinante vektoren auf der grundlage des modifizierten vacciniavirus ankara (mva) als impfstoffe gegen leishmaniase
WO2003091393A3 (en) Nucleic “acid molecules encoding human proteins, and uses thereof”